PMID- 35258097
OWN - NLM
STAT- MEDLINE
DCOM- 20220422
LR  - 20220422
IS  - 1099-0844 (Electronic)
IS  - 0263-6484 (Linking)
VI  - 40
IP  - 3
DP  - 2022 Apr
TI  - Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain 
      injury: A novel insight into targeted therapy.
PG  - 232-247
LID - 10.1002/cbf.3692 [doi]
AB  - Traumatic brain injury (TBI) is one of the most concerning health issues in which 
      the normal brain function may be disrupted as a result of a blow, bump, or jolt 
      to the head. Loss of consciousness, amnesia, focal neurological defects, 
      alteration in mental state, and destructive diseases of the nervous system such 
      as cognitive impairment, Parkinson's, and Alzheimer's disease. Parkinson's 
      disease is a chronic progressive neurodegenerative disorder, characterized by the 
      early loss of striatal dopaminergic neurons. TBI is a major risk factor for 
      Parkinson's disease. Existing therapeutic approaches have not been often 
      effective, indicating the necessity of discovering more efficient therapeutic 
      targets. The mammalian target of rapamycin (mTOR) signaling pathway responds to 
      different environmental cues to modulate a large number of cellular processes 
      such as cell proliferation, survival, protein synthesis, autophagy, and cell 
      metabolism. Moreover, mTOR has been reported to affect the regeneration of the 
      injured nerves throughout the central nervous system (CNS). In this context, 
      recent evaluations have revealed that mTOR inhibitors could be potential targets 
      to defeat a group of neurological disorders, and thus, a number of clinical 
      trials are investigating their efficacy in treating dementia, autism, epilepsy, 
      stroke, and brain injury, as irritating neurological defects. The current review 
      describes the interplay between mTOR signaling and major CNS-related disorders 
      (esp. neurodegenerative diseases), as well as the mTOR signaling-TBI 
      relationship. It also aims to discuss the promising therapeutic capacities of 
      mTOR inhibitors during the TBI.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Movahedpour, Ahmad
AU  - Movahedpour A
AD  - Behbahan Faculty of Medical Sciences, Behbahan, Iran.
FAU - Vakili, Omid
AU  - Vakili O
AD  - Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical 
      Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Khalifeh, Masoomeh
AU  - Khalifeh M
AD  - Department of Medical Biotechnology, School of Medicine, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
FAU - Mousavi, Pegah
AU  - Mousavi P
AD  - Department of Medical Genetics, Faculty of Medicine, Hormozgan University of 
      Medical Sciences, Bandar Abbas, Iran.
FAU - Mahmoodzadeh, Amir
AU  - Mahmoodzadeh A
AD  - Medical Biology Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran.
FAU - Taheri-Anganeh, Mortaza
AU  - Taheri-Anganeh M
AUID- ORCID: 0000-0002-9659-7491
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine 
      Institute, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Razmeh, Saeed
AU  - Razmeh S
AD  - Department of Internal Medicine, School of Medicine, Yasuj University of Medical 
      Sciences, Yasuj, Iran.
FAU - Shabaninejad, Zahra
AU  - Shabaninejad Z
AD  - Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Yousefi, Fatemeh
AU  - Yousefi F
AD  - Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Behrouj, Hamid
AU  - Behrouj H
AD  - Behbahan Faculty of Medical Sciences, Behbahan, Iran.
FAU - Ghasemi, Hassan
AU  - Ghasemi H
AUID- ORCID: 0000-0001-7809-2732
AD  - Abadan University of Medical Sciences, Abadan, Iran.
FAU - Khatami, Seyyed Hossein
AU  - Khatami SH
AUID- ORCID: 0000-0002-8579-5097
AD  - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
GR  - 1400U-1256/Abadan University of Medical Sciences/
PT  - Journal Article
PT  - Review
DEP - 20220308
PL  - England
TA  - Cell Biochem Funct
JT  - Cell biochemistry and function
JID - 8305874
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - *Brain Injuries, Traumatic/drug therapy
MH  - *Central Nervous System Diseases
MH  - Humans
MH  - *Neurodegenerative Diseases
MH  - *Parkinson Disease
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - TOR serine-threonine kinases
OT  - brain injuries
OT  - central nervous system
OT  - mTOR inhibitors
OT  - neurodegenerative diseases
EDAT- 2022/03/09 06:00
MHDA- 2022/04/23 06:00
CRDT- 2022/03/08 08:46
PHST- 2022/01/28 00:00 [revised]
PHST- 2021/10/28 00:00 [received]
PHST- 2022/02/02 00:00 [accepted]
PHST- 2022/03/09 06:00 [pubmed]
PHST- 2022/04/23 06:00 [medline]
PHST- 2022/03/08 08:46 [entrez]
AID - 10.1002/cbf.3692 [doi]
PST - ppublish
SO  - Cell Biochem Funct. 2022 Apr;40(3):232-247. doi: 10.1002/cbf.3692. Epub 2022 Mar 
      8.